John L. Hays, MD

John L. Hays, MD

Associate Professor, Department of Internal Medicine

Medical Director of the Clinical Trials Office

The Ohio State University College of Medicine

Wexner Medical Center & James Cancer Hospital

Columbus, OH

Related Videos

What were the specific endpoints for ARTISTRY-7 and how will the trial results translate into possible approvals for nemvaleukin and/or ICIs for platinum-resistant ovarian cancer (PROC)? Video

What were the specific endpoints for ARTISTRY-7 and how will the trial results translate into possible approvals for nemvaleukin and/or ICIs for platinum-resistant ovarian cancer (PROC)?

While the formidable challenges of treating platinum-resistant ovarian cancer are well known, can you summarize the current, approaches for treating these patient cohorts, and specifically, the trigger points and reported outcomes for immunotherapy? Video

While the formidable challenges of treating platinum-resistant ovarian cancer are well known, can you summarize the current, approaches for treating these patient cohorts, and specifically, the trigger points and reported outcomes for immunotherapy?

Based on the accumulated data thus far from ARTISTRY-1 and interim monitoring, can you characterize the side effect profile and regimen discontinuation rates observed thus far for nemvaleukin, and its manageability in the outpatient setting? Video

Based on the accumulated data thus far from ARTISTRY-1 and interim monitoring, can you characterize the side effect profile and regimen discontinuation rates observed thus far for nemvaleukin, and its manageability in the outpatient setting?

What do you hope to learn from ARTISTRY-7 as it relates to the efficacy and safety of nemvaleukin as monotherapy or as part of combinatorial therapy with immune checkpoint inhibitors and, even, chemotoxic agents in the setting of solid tumors? Video

What do you hope to learn from ARTISTRY-7 as it relates to the efficacy and safety of nemvaleukin as monotherapy or as part of combinatorial therapy with immune checkpoint inhibitors and, even, chemotoxic agents in the setting of solid tumors?

What were the design, rationale, inclusionary criteria, and results of the ARTISTRY-1 trial, in which nemvaleukin was evaluated in a Phase 1 trial to elucidate dosing and signals suggesting efficacy across a broad range of solid tumors? Video

What were the design, rationale, inclusionary criteria, and results of the ARTISTRY-1 trial, in which nemvaleukin was evaluated in a Phase 1 trial to elucidate dosing and signals suggesting efficacy across a broad range of solid tumors?

In addition to the ARTISTRY-7 nemvaleukin trial, what other I-O strategies are being investigated in PROC? Video

In addition to the ARTISTRY-7 nemvaleukin trial, what other I-O strategies are being investigated in PROC?

So that our learners can better understand your experience, investigational interests, and expertise in cancer immunotherapy and multi-modal management of ovarian cancer can you kindly share your current role and affiliations? Video

So that our learners can better understand your experience, investigational interests, and expertise in cancer immunotherapy and multi-modal management of ovarian cancer can you kindly share your current role and affiliations?

Given the refractoriness of platinum-resistant OC what does the investigational immunotherapy landscape look like for this patient subset with OC, including the use of immune checkpoint inhibitors and cytokine fusion proteins such as nemvaleukin? Video

Given the refractoriness of platinum-resistant OC what does the investigational immunotherapy landscape look like for this patient subset with OC, including the use of immune checkpoint inhibitors and cytokine fusion proteins such as nemvaleukin?

Based on the results/signals observed in OC patients in ARTISTRY-1, how do you design a translationally optimal trial with nemvaleukin to assess its effectives as a monotherapeutic vs. combinatorial agent? Video

Based on the results/signals observed in OC patients in ARTISTRY-1, how do you design a translationally optimal trial with nemvaleukin to assess its effectives as a monotherapeutic vs. combinatorial agent?